Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study

Blood (2024) 144 (Supplement 1): 2424.

https://doi.org/10.1182/blood-2024-207226

Published: 2024

Journal Articles

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Blood (2024) 144 (Supplement 1): 478.

https://doi.org/10.1182/blood-2024-198903

Published: 2024

Journal Articles

Air Transfer of Patients with Newly Diagnosed Acute Myeloid Leukemia: The Experience of French Polynesia

Blood (2023) 142 (Supplement 1): 5861.

https://doi.org/10.1182/blood-2023-181567

Published: 2023

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Journal Articles

Reduced Post-Transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation

Remy Dulery, Florent Malard, Eolia Brissot, Anne Banet, Simona Sestili, Ramdane Belhocine, Martina Calabrò, Zoé Van De Wyngaert, Agnès Bonnin, Tounes Ledraa, Ollivier Legrand, Myriam Labopin, Elodie Capderou, Ariel Cohen, Stéphane Ederhy, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 10517–10518.

https://doi.org/10.1182/blood-2022-165104

Published: 2022

Journal Articles

Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin

Blood (2021) 138 (Supplement 1): 876.

https://doi.org/10.1182/blood-2021-145184

Published: 2021

Journal Articles

Sequential Conditioning Regimen with Thiotepa in Allogeneic Hematopoietic Cell Transplantation for the Treatment of Refractory Myeloid Malignancies

Blood (2021) 138 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2021-150498

Published: 2021

Journal Articles

Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

Jorge Sierra, MD, Pau Montesinos, MD PhD, Xavier Thomas, MD PhD, Laimonas Griškevičius, MD PhD, Thomas Cluzeau, MD PhD, Denis Caillot, Ollivier Legrand, MD, Clara Minotti, MD, Mario Luppi, Firas Farkas, MD, Bourras-Rezki Bengoudifa, MS, Geralyn Gilotti, MSc, Sejla Hodzic, MD, Alessandro Rambaldi, MD PhD, Adriano Venditti, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136083

Published: 2020

Journal Articles

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

Blood (2018) 132 (Supplement 1): 1444.

https://doi.org/10.1182/blood-2018-99-112825

Published: 2018

Journal Articles

Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Cécile Pautas, Emmanuel Raffoux, MD, Juliette Lambert, Ollivier Legrand, MD PhD, Rebecca J Benner, Erik R. Vandendries, MD PhD, Karïn Gogat, Hervé Dombret, MD, Sylvie Castaigne, MD

Blood (2018) 132 (Supplement 1): 28.

https://doi.org/10.1182/blood-2018-99-111251

Published: 2018

Journal Articles

Fractionated Gemtuzumab Ozogamicin in Association with High Dose Chemotherapy: A Bridge to Allogeneic Stem Cell Transplantation in Refractory and Relapsed Acute Myeloid Leukemia?

Pierre-Edouard Debureaux, Myriam Labopin, MD PhD, Simona Lapusan, MD, Francoise Isnard, PhD, Rosa Adaeva, Agnès Bonnin, Pierre Hirsch, MDPhD, Francois Delhommeau, MD PhD, Giorgia Battipaglia, MD, Remy Duléry, MD, Federica Giannotti, MD, Florent Malard, MDPhD, Annalisa Ruggeri, MD, Anne Vekhoff, Ollivier Legrand, MD PhD, Mohamad Mohty, MD PhD, Eolia Brissot, MDPhD

Blood (2017) 130 (Supplement 1): 4603.

https://doi.org/10.1182/blood.V130.Suppl_1.4603.4603

Published: 2017

Journal Articles

Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial

Mohamad Mohty, MD PhD, Florent Malard, MDPhD, Evelyne D'Incan, MD, Xavier Thomas, MD, Christian Recher, MD PhD, Anne-Sophie Michallet, MD PhD, Pierre Peterlin, MD, Anne Vekhoff, Norbert Vey, Emilie Plantamura, Philippe Lehert, Joel Doré, Ollivier Legrand, MD PhD

Blood (2017) 130 (Supplement 1): 2624.

https://doi.org/10.1182/blood.V130.Suppl_1.2624.2624

Published: 2017

Journal Articles

Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia

Blood (2016) 128 (22): 4624.

https://doi.org/10.1182/blood.V128.22.4624.4624

Published: 2016

Journal Articles

Texture Analysis on Computed Tomography Predicts the Outcome of Patients with Hodgkin Lymphoma

Remy Dulery, MD, Anthony Dohan, MD, Maxime Barat, Mor Seny Gueye, Catherine Phan, MD, Zora Marjanovic, MD, Malek Aoudjhane, MD, Elise Corre, MD, Marie-Paule Lemonnier, MD, Anne Vekhoff, MD, Laurent Garderet, MD PhD, Ollivier Legrand, MD PhD, Paul Coppo, MD PhD, Philippe Soyer, MD PhD, Caroline Reinhold, MD, Lionel Arrivé, MD PhD, Benoit Gallix, MD PhD, Mohamad Mohty, MD PhD

Blood (2016) 128 (22): 1832.

https://doi.org/10.1182/blood.V128.22.1832.1832

Published: 2016

Journal Articles

Clono-Specific Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia

Pierre Hirsch, Ruoping Tang, Nassera Abermil, Pascale Flandrin, Hannah Moatti, Mohamad Mohty, MD PhD, Ollivier Legrand, MD PhD, Luc Douay, MD PhD, Chrystele bilhou Nabera, Francois Delhommeau

Blood (2016) 128 (22): 1208.

https://doi.org/10.1182/blood.V128.22.1208.1208

Published: 2016

Journal Articles

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia

Blood (2016) 127 (17): 2157–2160.

https://doi.org/10.1182/blood-2016-01-689976

Published: 2016

Includes: Supplemental data

Journal Articles

Targeting Acute Myeloid Leukemia with a New CXCR4 Antagonist IgG1 Antibody (PF-06747143)in NOD/SCID Mice

Yanyan Zhang, PhD, Erika Saavedra, MD, Ruoping Tang, Shu-Hui Liu, Tod Smeal, Valeria Fantin, PhD, Stephane De Botton, MD PhD, Ollivier Legrand, MD PhD, William Vainchenker, MD PhD, Flavia Pernasetti, Fawzia Louache, PhD

Blood (2015) 126 (23): 1362.

https://doi.org/10.1182/blood.V126.23.1362.1362

Published: 2015

Journal Articles

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Blood (2014) 124 (21): 1823.

https://doi.org/10.1182/blood.V124.21.1823.1823

Published: 2014

Journal Articles

Impact of FLT3-ITD Mutational Burden in 469 Acute Myeloid Leukemia (AML) Patients

Pierre Hirsch, MD, Myriam Labopin, Christophe Marzac, MD, Anne-Claire Mamez, MD, Ruoping Tang, Françoise Isnard, MD, Simona Lapusan, Anne Vekhoff, MD, Norbert C Gorin, MD, Jean-Pierre Marie, Mohamad Mohty, Ollivier Legrand, MD PhD

Blood (2014) 124 (21): 1033.

https://doi.org/10.1182/blood.V124.21.1033.1033

Published: 2014

Journal Articles

Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML)

Emmanuelle Kempf, Pierre Hirsch, Myriam Labopin, Christophe Marzac, MD, Jean-Yves Perrot, Françoise Isnard, MD, Jean-Pierre Marie, MD, Mohamad Mohty, MD, PhD, Ollivier Legrand, MD, PhD

Blood (2013) 122 (21): 2658.

https://doi.org/10.1182/blood.V122.21.2658.2658

Published: 2013

NARROW

Treatments and Outcomes of Adult Patients with AML in the Real-Life - First Report of the French Observational ALFA-PPP Study

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Air Transfer of Patients with Newly Diagnosed Acute Myeloid Leukemia: The Experience of French Polynesia

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Reduced Post-Transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation

Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin

Sequential Conditioning Regimen with Thiotepa in Allogeneic Hematopoietic Cell Transplantation for the Treatment of Refractory Myeloid Malignancies

Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Fractionated Gemtuzumab Ozogamicin in Association with High Dose Chemotherapy: A Bridge to Allogeneic Stem Cell Transplantation in Refractory and Relapsed Acute Myeloid Leukemia?

Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial

Efficacy and Feasibility of Sorafenib As a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia

Texture Analysis on Computed Tomography Predicts the Outcome of Patients with Hodgkin Lymphoma

Clono-Specific Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia

Targeting Acute Myeloid Leukemia with a New CXCR4 Antagonist IgG1 Antibody (PF-06747143)in NOD/SCID Mice

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Impact of FLT3-ITD Mutational Burden in 469 Acute Myeloid Leukemia (AML) Patients

Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only